Discovery services in oncology, immunology and respiratory
Cellvanta is a boutique life sciences advisory company supporting biotech organisations, technology developers and ecosystem partners across cell therapy development. We provide specialist technical and strategic expertise to address complex analytical, CMC and product development challenges and support informed development, investment and partnership decisions.
With deep expertise in cell therapy and analytical development, Cellvanta provides advisory support across potency and functional assay strategy, product characterisation, critical quality attribute identification, comparability, analytical gap assessment, assay qualification and technology transfer. Our expertise includes advanced flow cytometry and cell-based assay development, alongside broader analytical development and CMC strategy.
Cellvanta also provides independent technical due diligence, helping investors, developers and partners assess scientific evidence, development strategy, technical risk and the maturity of emerging technologies and therapeutic programmes.
Cellvanta is led by Siddharth Krishnan, PhD, drawing on hands-on advanced therapy development experience across industry and translational environments.
Enquiries:
Siddharth Krishnan, PhD
Founder & Director, Cellvanta Ltd
With deep expertise in cell therapy and analytical development, Cellvanta provides advisory support across potency and functional assay strategy, product characterisation, critical quality attribute identification, comparability, analytical gap assessment, assay qualification and technology transfer. Our expertise includes advanced flow cytometry and cell-based assay development, alongside broader analytical development and CMC strategy.
Cellvanta also provides independent technical due diligence, helping investors, developers and partners assess scientific evidence, development strategy, technical risk and the maturity of emerging technologies and therapeutic programmes.
Cellvanta is led by Siddharth Krishnan, PhD, drawing on hands-on advanced therapy development experience across industry and translational environments.
Enquiries:
Siddharth Krishnan, PhD
Founder & Director, Cellvanta Ltd
CPI provides assets and resources to support innovations in the manufacture of biologics. Utilising our state of the art facilities and technical expertise, we help our clients to de-risk process development through proof of concept testing to accelerate the commercialisation of new processes and technologies. . . Our skilled team of scientists, engineers and sector specialists can help companies of all sizes to develop, demonstrate, prototype and scale-up innovations that could be beneficial to biologics manufacture and provision. From initial programme scoping and planning through to process demonstration and scale-up we have a range of services which can be tailored to meet your needs. . . Collaboration with CPI will enable the biologics industry to capitalise on its strong research and development pipeline and make more therapies available for unmet clinical needs. We support the commercialisation of research by promoting collaboration with industry across the supply chain from research through to manufacture and clinic.
CFGI is an international, non-audit, accounting advisory firm free of auditor independence restrictions. Consisting of ex-Big4 professionals, CFGI is strategically positioned to help companies and private equity sponsors through a range of routine and complex business scenarios.
Founded in the US in 2000, and now operating across the UK, CFGI is ideally placed to support companies throughout their lifecycle, from ambitious high growth pre-revenue start-ups, right through to established, commercial public companies. CFGI has expertise across a wide range of sectors, with a particular specialism in Lifesciences and Healthcare.
Operating as a hands-on extension of your finance team, CFGI works alongside your people, serving in a variety of roles – from technical accounting advisor to M&A support, to IPO readiness to listed company financial reporting – and delivering seamless support services. Without the independence restrictions of an audit practice, CFGI’s model allows for a rapid, flexible and cost competitive response to deliver a tailored solution for each challenge encountered.
The range of areas of support include:
» Technical accounting
» IPO readiness and support
» Interim management
» Valuation
» Audit assistance
» Cybersecurity
» Risk advisory and controls
» Transaction services
» ESG implementation
» Financial reporting
» Business transformation
» Tax services
https://www.cfgi.com
Contact Paul Cooper our UK Healthcare and Lifesciences lead at [email protected]
Founded in the US in 2000, and now operating across the UK, CFGI is ideally placed to support companies throughout their lifecycle, from ambitious high growth pre-revenue start-ups, right through to established, commercial public companies. CFGI has expertise across a wide range of sectors, with a particular specialism in Lifesciences and Healthcare.
Operating as a hands-on extension of your finance team, CFGI works alongside your people, serving in a variety of roles – from technical accounting advisor to M&A support, to IPO readiness to listed company financial reporting – and delivering seamless support services. Without the independence restrictions of an audit practice, CFGI’s model allows for a rapid, flexible and cost competitive response to deliver a tailored solution for each challenge encountered.
The range of areas of support include:
» Technical accounting
» IPO readiness and support
» Interim management
» Valuation
» Audit assistance
» Cybersecurity
» Risk advisory and controls
» Transaction services
» ESG implementation
» Financial reporting
» Business transformation
» Tax services
https://www.cfgi.com
Contact Paul Cooper our UK Healthcare and Lifesciences lead at [email protected]
No data available
Near the end of 2020, Deepmind announced that they had solved of the protein folding problem, a "50-year-old grand challenge in biology". Their approach was end-to-end deep learning, and it was the first time deep learning had solved an important scientific problem.
We believe this along with other recent breakthroughs in deep learning on 3D molecular configurations are the start of a new era in drug discovery, akin to the what AlexNet did for computer vision in 2012. Inspired by these breakthroughs, **CHARM Therapeutics** was founded with the mission to harness the power of deep learning to deliver medicines of transformational efficacy for patients.
We believe this along with other recent breakthroughs in deep learning on 3D molecular configurations are the start of a new era in drug discovery, akin to the what AlexNet did for computer vision in 2012. Inspired by these breakthroughs, **CHARM Therapeutics** was founded with the mission to harness the power of deep learning to deliver medicines of transformational efficacy for patients.
Cheffins is an established Cambridge-based property consultancy providing independent and expert advice focused on the technology sector. Our advice and experience covers the full range of property issues including development, acquisitions and disposals, rent reviews and lease renewals, surveys and dilapidation claims plus general strategic advice. Clients in this sector for whom we have worked range from investors such as BioMed Realty, Churchmanor Estates and Aviva Investors to occupiers, including the Medical Research Council, Abcam, Lonza Biologics and Bayer.
No data available
CMS is a full service law firm with a network of offices across Europe and beyond. We are leaders in the life sciences sector and have a strong track record of working with early-stage spin-outs through to major global companies. The sector presents its own unique challenges and needs. We have a team focused on building relationships and expertise required to deliver relevant advice. Our clients benefit from commercial no-nonsense advice, whether they are longstanding clients or prospective clients needing a second opinion or advice where others are conflicted. Our clients value our commercial advice, which is delivered at competitive prices.
CN Bio Innovations develops human organ-on-a-chip technologies: devices that enable the formation of miniature models of organs in the lab using living human cells. In 2016 we successsfully showcased the world's first 7-organ-on-a-chip platform. Over the past three years more than 25 pharmaceutical companies have used our devices to study the effects of drugs and other chemicals on organ function. CN Bio is also developing organ-on-a-chip models for specific diseases, including non-alcoholic steatohepatitis and hepatitis B. CN Bio is a co-recipient with MIT of a $26 million federal contract to develop next generation organs-on-chips and has also received InnovateUK grant awards.